Moxifloxacin

證據等級: L5

預測適應症: 10 個

Moxifloxacin: From Bacterial Infections to Bubonic Plague

One-Sentence Summary

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic; specific original-indication licensing data is not yet available for this market, though its class-level use for common bacterial infections is well established. Of the 10 TxGNN-predicted indications screened for this drug, only Bubonic Plague reached a substantive evidence stage, supported by 6 publications (animal/in vitro PK-PD efficacy studies) and no completed clinical trials — human RCTs are not feasible for this indication. The remaining 9 predictions (e.g. hyperamylasemia, monoclonal gammopathy, congenital hematological disorder) show no mechanistic or evidentiary support and are classified as low-confidence screening noise.

Quick Overview

Item	Content
Original Indication	No approved-indication data on file (drug not yet marketed here); pharmacologically a broad-spectrum 4th-generation fluoroquinolone antibiotic
Predicted New Indication	Bubonic Plague
TxGNN Prediction Score	99.41%
Evidence Level	L3
New Zealand Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, moxifloxacin belongs to the fourth-generation fluoroquinolone class, inhibiting bacterial DNA gyrase and topoisomerase IV to block DNA replication. Its efficacy against a broad range of gram-positive and gram-negative bacteria is well established in clinical use.

Yersinia pestis, the causative agent of bubonic plague, is a gram-negative bacillus that falls squarely within the antibacterial spectrum fluoroquinolones are known to cover. This is therefore not a novel off-target repurposing signal in the way TxGNN predictions usually work — it is a direct extension of moxifloxacin's existing antimicrobial mechanism to an additional susceptible pathogen.

Because human RCTs for plague are neither ethical nor practically feasible (the disease is rare and rapidly lethal untreated), the standard evidentiary pathway for this indication is the FDA "Animal Rule" — efficacy demonstrated through animal models and in vitro pharmacokinetic/pharmacodynamic (PK/PD) studies, which is exactly the evidence base found here (multiple mouse-model and in vitro PK/PD studies against Y. pestis).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21115791	2011	In vitro PK/PD model	Antimicrobial Agents and Chemotherapy	Derived a moxifloxacin dosing regimen via in vitro PK/PD model that optimizes killing of Y. pestis and prevents emergence of resistance
20052916	2009	Animal efficacy (comparative)	Antibiotiki i khimioterapiia	Moxifloxacin ED50 5.5–14.0 mg/kg against FI+/FI- Y. pestis strains in a mouse infection model, comparable to levofloxacin
15555886	2004	Animal efficacy	International Journal of Antimicrobial Agents	Moxifloxacin gave full protection up to 6h (systemic) and 30h (aerosol) post-challenge in a mouse plague model, comparable to ciprofloxacin
21486959	2011	In vitro comparative efficacy	Antimicrobial Agents and Chemotherapy	Compared candidate antibiotics, including moxifloxacin, against Y. pestis in an in vitro PK/PD model relative to streptomycin gold standard
29623187	2018	Case report (adverse event)	Therapeutic Advances in Drug Safety	Case of moxifloxacin-induced tinnitus in an older adult; notes FDA-recommended fluoroquinolone use is limited to specific infections including plague
26210091	2015	Case report (related pathogen)	Ticks and Tick-borne Diseases	Case of Francisella tularensis (a related CDC Category A biothreat pathogen) infection in China; tangential relevance to biothreat antibiotic planning

Safety Considerations

Please refer to the package insert for safety information.

Other TxGNN-Predicted Indications (Screened, Not Pursued)

Of the 10 candidates in this evidence pack, 9 were assessed as low-confidence screening noise (Evidence Level L4–L5, decision stage S0–S1, recommendation Hold or Research Question), with either no clinical/literature evidence at all, or evidence limited to incidental antibiotic use during infections in patients who happen to have the predicted disease (e.g. monoclonal gammopathy, congenital hematological disorder) rather than any treatment effect on the disease itself:

hyperamylasemia, polyclonal hyperviscosity syndrome, congenital analbuminemia, blood group incompatibility, premalignant hematological system disease, monoclonal gammopathy, hematological disease associated with acquired peripheral neuropathy, congenital hematological disorder, hematopoietic and lymphoid system neoplasm.

These should not be advanced without new, disease-specific mechanistic or trial evidence.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for Bubonic Plague only; all other predicted indications: Hold)

Rationale: Bubonic plague is the only candidate with a coherent mechanistic basis (established fluoroquinolone activity against Y. pestis) and multiple independent animal/in vitro PK-PD studies confirming efficacy — the accepted evidence standard for this indication under the FDA Animal Rule. However, this is a direct antimicrobial-spectrum extension rather than a genuine drug-repurposing discovery, and local regulatory/safety documentation is currently missing.

To proceed, the following is needed:

TFDA/local package insert with warnings and contraindications (currently blocking — DG001)
Formal mechanism-of-action documentation (currently missing — DG002)
Confirmation of local regulatory pathway equivalent to the FDA Animal Rule for biothreat indications
Drug-drug interaction data (current query returned no results)
A biopreparedness-specific use case and stakeholder (public health authority) engagement plan, since this is not a conventional commercial indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.